Review



pbpk model commercial software gastroplus  (Simulations Plus Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Simulations Plus Inc pbpk model commercial software gastroplus
    Validation results of the <t>PBPK</t> model with different dosing regimens (the solid line is the prediction result and the dashed line is the validation result).
    Pbpk Model Commercial Software Gastroplus, supplied by Simulations Plus Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pbpk+model+commercial+software+gastroplus/pmc08779920-90-12-19?v=Simulations+Plus+Inc
    Average 90 stars, based on 1 article reviews
    pbpk model commercial software gastroplus - by Bioz Stars, 2026-07
    90/100 stars

    Images

    1) Product Images from "In Vitro and In Vivo Bioequivalence Study of 3D-Printed Instant-Dissolving Levetiracetam Tablets and Subsequent Personalized Dosing for Chinese Children Based on Physiological Pharmacokinetic Modeling"

    Article Title: In Vitro and In Vivo Bioequivalence Study of 3D-Printed Instant-Dissolving Levetiracetam Tablets and Subsequent Personalized Dosing for Chinese Children Based on Physiological Pharmacokinetic Modeling

    Journal: Pharmaceutics

    doi: 10.3390/pharmaceutics14010020

    Validation results of the PBPK model with different dosing regimens (the solid line is the prediction result and the dashed line is the validation result).
    Figure Legend Snippet: Validation results of the PBPK model with different dosing regimens (the solid line is the prediction result and the dashed line is the validation result).

    Techniques Used: Biomarker Discovery

    Prediction results of the oral LEV PBPK model in the Chinese pediatric population.
    Figure Legend Snippet: Prediction results of the oral LEV PBPK model in the Chinese pediatric population.

    Techniques Used:

    Predicted results of the oral PBPK model in 4-year-old Chinese children. ( A ) 177.8 mg, q 12 h; ( B ) 300 mg + 200 mg, q 12 h.
    Figure Legend Snippet: Predicted results of the oral PBPK model in 4-year-old Chinese children. ( A ) 177.8 mg, q 12 h; ( B ) 300 mg + 200 mg, q 12 h.

    Techniques Used:

    Prediction results of the 280 mg + 222.6 mg oral LEV-PBPK model in 6-year-old Chinese children. ( A ) Seven-day drug–time curve after normal administration; ( B ) 300 mg drug–time curve after remediation of a missed dose; ( C ) 275 mg drug–time curve after a missed dose; ( D ) 350 mg drug–time curve after remediation of a missed dose.
    Figure Legend Snippet: Prediction results of the 280 mg + 222.6 mg oral LEV-PBPK model in 6-year-old Chinese children. ( A ) Seven-day drug–time curve after normal administration; ( B ) 300 mg drug–time curve after remediation of a missed dose; ( C ) 275 mg drug–time curve after a missed dose; ( D ) 350 mg drug–time curve after remediation of a missed dose.

    Techniques Used:



    Similar Products

    pbpk model commercial software gastroplus  (Simulations Plus Inc)
    90
    Simulations Plus Inc pbpk model commercial software gastroplus
    Validation results of the <t>PBPK</t> model with different dosing regimens (the solid line is the prediction result and the dashed line is the validation result).
    Pbpk Model Commercial Software Gastroplus, supplied by Simulations Plus Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pbpk+model+commercial+software+gastroplus/pmc08779920-90-12-19?v=Simulations+Plus+Inc
    Average 90 stars, based on 1 article reviews
    pbpk model commercial software gastroplus - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Validation results of the PBPK model with different dosing regimens (the solid line is the prediction result and the dashed line is the validation result).

    Journal: Pharmaceutics

    Article Title: In Vitro and In Vivo Bioequivalence Study of 3D-Printed Instant-Dissolving Levetiracetam Tablets and Subsequent Personalized Dosing for Chinese Children Based on Physiological Pharmacokinetic Modeling

    doi: 10.3390/pharmaceutics14010020

    Figure Lengend Snippet: Validation results of the PBPK model with different dosing regimens (the solid line is the prediction result and the dashed line is the validation result).

    Article Snippet: All in vivo PK simulations in this study were performed in the PBPK model commercial software GastroPlus (Version 9.8, Simulations Plus, Inc., Lancaster, PA, USA).

    Techniques: Biomarker Discovery

    Prediction results of the oral LEV PBPK model in the Chinese pediatric population.

    Journal: Pharmaceutics

    Article Title: In Vitro and In Vivo Bioequivalence Study of 3D-Printed Instant-Dissolving Levetiracetam Tablets and Subsequent Personalized Dosing for Chinese Children Based on Physiological Pharmacokinetic Modeling

    doi: 10.3390/pharmaceutics14010020

    Figure Lengend Snippet: Prediction results of the oral LEV PBPK model in the Chinese pediatric population.

    Article Snippet: All in vivo PK simulations in this study were performed in the PBPK model commercial software GastroPlus (Version 9.8, Simulations Plus, Inc., Lancaster, PA, USA).

    Techniques:

    Predicted results of the oral PBPK model in 4-year-old Chinese children. ( A ) 177.8 mg, q 12 h; ( B ) 300 mg + 200 mg, q 12 h.

    Journal: Pharmaceutics

    Article Title: In Vitro and In Vivo Bioequivalence Study of 3D-Printed Instant-Dissolving Levetiracetam Tablets and Subsequent Personalized Dosing for Chinese Children Based on Physiological Pharmacokinetic Modeling

    doi: 10.3390/pharmaceutics14010020

    Figure Lengend Snippet: Predicted results of the oral PBPK model in 4-year-old Chinese children. ( A ) 177.8 mg, q 12 h; ( B ) 300 mg + 200 mg, q 12 h.

    Article Snippet: All in vivo PK simulations in this study were performed in the PBPK model commercial software GastroPlus (Version 9.8, Simulations Plus, Inc., Lancaster, PA, USA).

    Techniques:

    Prediction results of the 280 mg + 222.6 mg oral LEV-PBPK model in 6-year-old Chinese children. ( A ) Seven-day drug–time curve after normal administration; ( B ) 300 mg drug–time curve after remediation of a missed dose; ( C ) 275 mg drug–time curve after a missed dose; ( D ) 350 mg drug–time curve after remediation of a missed dose.

    Journal: Pharmaceutics

    Article Title: In Vitro and In Vivo Bioequivalence Study of 3D-Printed Instant-Dissolving Levetiracetam Tablets and Subsequent Personalized Dosing for Chinese Children Based on Physiological Pharmacokinetic Modeling

    doi: 10.3390/pharmaceutics14010020

    Figure Lengend Snippet: Prediction results of the 280 mg + 222.6 mg oral LEV-PBPK model in 6-year-old Chinese children. ( A ) Seven-day drug–time curve after normal administration; ( B ) 300 mg drug–time curve after remediation of a missed dose; ( C ) 275 mg drug–time curve after a missed dose; ( D ) 350 mg drug–time curve after remediation of a missed dose.

    Article Snippet: All in vivo PK simulations in this study were performed in the PBPK model commercial software GastroPlus (Version 9.8, Simulations Plus, Inc., Lancaster, PA, USA).

    Techniques: